Literature DB >> 15647815

An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.

Michael T Collins1, Harvey Kushner, James C Reynolds, Caroline Chebli, Marilyn H Kelly, Anurag Gupta, Beth Brillante, Arabella I Leet, Mara Riminucci, Pamela Gehron Robey, Paolo Bianco, Shlomo Wientroub, Clara C Chen.   

Abstract

UNLABELLED: An instrument to measure skeletal burden in fibrous dysplasia was developed. Biological and clinical relevance was shown by correlating skeletal burden scores with bone markers, quality of life, and ambulatory status. Childhood scores predict adult ambulatory status, and scores were unaffected when bone markers decreased with bisphosphonate treatment or aging.
INTRODUCTION: Fibrous dysplasia (FD) is a skeletal disease with a broad clinical expression. There is no objective method to assess the extent of skeletal involvement or predict outcome. We developed an instrument to measure skeletal burden that correlates with physical function, health-related quality of life (HRQL), and ambulatory status.
MATERIALS AND METHODS: Seventy-nine patients with FD underwent bone scintigraphy. The skeletal burden score was derived from a weighted score based on the regional measurement using bone scintigraphy to estimate the amount of FD in anatomical segments. Six readers scored 20 scans twice to determine the inter- and intrareader agreement. To assess biological significance, scores were correlated with bone markers. To assess functional outcome, scores on the SF-36 (adults) or CHQ-PF50 (children) were correlated with skeletal burden scores. In a group of patients who had bone scans as children and adults (n = 6), the ability to predict ambulatory status was tested. Skeletal burden scores were assessed in patients before and after treatment with pamidronate (n = 5).
RESULTS: The inter- and intrareader agreement of burden scores were r = 0.96, and 0.98, respectively (p < 0.001 for both). The scores correlated with markers of bone metabolism and HRQL (Spearman rho, 0.54-0.67 p < 0.001 and -0.43, p = 0.001, respectively). The mean score of patients who ambulated unassisted was significantly lower than those requiring assistance (p < 0.001 unassisted versus crutch and/or wheelchair). In unassisted ambulators, younger patients had higher scores, suggesting high childhood scores may predict adulthood impairment. In six patients with childhood and adulthood scans, childhood scores >30 predicted assisted ambulation in adulthood. There was a negative correlation between bone markers and age (Spearman rho, -0.42 to -0.70; p < 0.001), but not age and skeletal burden score. Pamidronate treatment decreased serum alkaline phosphatase but had no effect on the skeletal burden score.
CONCLUSIONS: This is a validated and reliable instrument for the measurement of skeletal burden of FD and is able to predict functional outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15647815     DOI: 10.1359/JBMR.041111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  39 in total

1.  Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia.

Authors:  Scott M Paul; Lisa R Gabor; Scott Rudzinski; David Giovanni; Alison M Boyce; Marilyn R N Kelly; Michael T Collins
Journal:  Bone       Date:  2013-12-04       Impact factor: 4.398

2.  Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.

Authors:  Sunday O Akintoye; Alison M Boyce; Michael T Collins
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-09

3.  Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.

Authors:  Wouter van der Bruggen; Marlous Hagelstein-Rotman; Lioe-Fee de Geus-Oei; Frits Smit; P D Sander Dijkstra; Natasha M Appelman-Dijkstra; Dennis Vriens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-24       Impact factor: 9.236

4.  Fibrous Dysplasia Mimicking Malignancy on 68Ga-DOTATATE PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Samira M Sadowski; Apostolos H Karantanas; Ulas Bagci; Nicholas J Patronas
Journal:  Clin Nucl Med       Date:  2017-03       Impact factor: 7.794

5.  Improving patient outcomes in fibrous dysplasia/McCune-Albright syndrome: an international multidisciplinary workshop to inform an international partnership.

Authors:  A M Boyce; A Turner; L Watts; L Forestier-Zhang; A Underhill; R Pinedo-Villanueva; F Monsell; D Tessaris; C Burren; L Masi; N Hamdy; M L Brandi; R Chapurlat; M T Collins; Muhammad Kassim Javaid
Journal:  Arch Osteoporos       Date:  2017-02-27       Impact factor: 2.617

6.  Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.

Authors:  Pablo Florenzano; Kristen S Pan; Sydney M Brown; Scott M Paul; Harvey Kushner; Lori C Guthrie; Luis Fernandez de Castro; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2019-01-15       Impact factor: 6.741

7.  Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess.

Authors:  Alison M Boyce; McKinley Glover; Marilyn H Kelly; Beth A Brillante; John A Butman; Edmond J Fitzgibbon; Carmen C Brewer; Christopher K Zalewski; Carolee M Cutler Peck; H Jeffrey Kim; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2012-10-23       Impact factor: 5.958

Review 8.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

9.  Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report.

Authors:  Gui-Dong Li; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Takashi Ariizumi; Yongjun Xu; Naoto Endo
Journal:  Oncol Lett       Date:  2011-08-02       Impact factor: 2.967

Review 10.  Fibrous dysplasia and fibroblast growth factor-23 regulation.

Authors:  Alison M Boyce; Nisan Bhattacharyya; Michael T Collins
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.